Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amifampridine - BioMarin

Next Previous
Drug Profile

Amifampridine - BioMarin

Alternative Names: 3,4-DAP; 3,4-DAP phosphate; 3,4-DAPP; 3,4-Diaminopyridine; 3,4-Pyridinediamine-phosphate; Amifampridine phosphate; DAPP; Firdapse; Pyridine-3,4-diamine-monophosphate; Zenas

Latest Information Update: 24 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Assistance Publique Hopitaux de Paris
  • Developer BioMarin Pharmaceutical; Catalyst Pharmaceuticals; DyDo Pharma; Fondazione Istituto Neurologico Carlo Besta; KYE Pharmaceuticals
  • Class Aminopyridines; Antineoplastics; Small molecules
  • Mechanism of Action Acetylcholine stimulants; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lambert-Eaton myasthenic syndrome; Myasthenia gravis; Congenital myasthenic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lambert-Eaton myasthenic syndrome
  • Phase III Congenital myasthenic syndromes; Myasthenia gravis
  • Discontinued Spinal muscular atrophy

Most Recent Events

  • 18 Jun 2025 Registered for Lambert-Eaton myasthenic syndrome (In children) in Canada (PO)
  • 18 Jun 2025 Health Canada has approved Supplemental New Drug application regarding the recommended dosage for amifampridine (In adults) for Lambert-Eaton myasthenic syndrome
  • 21 Jan 2025 Launched for Lambert-Eaton myasthenic syndrome in Japan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top